MedPage Today on MSN
CAR7 gene therapy shows promise in T-cell ALL
One patient still in remission 3 years after single infusion of base-edited CAR7 T cells ...
The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results